×
About 2,590 results

ALLMedicine™ Hemolytic Uremic Syndrome Center

Research & Reviews  929 results

SERPINB11 variant-related liver injury in STEC-HUS: case reports and literature review.
https://doi.org/10.1007/s00467-022-05602-5 10.1016/S0140-6736(17)30062-4 10.1007/s00467-020-04560-0 10.1055/s-2007-965013 10.1055/s-0042-108444 10.1053/jpsu.2001.28858 10.1016/j.jhep.2014.06.038 10.7326/0003-4819-137-12-200212170-00007 10.14309/ctg.0000000000000087 10.1097/00005176-200403000-00022 10.1007/BF00858990 10.1007/s00018-003-3240-3 10.1074/jbc.M703182200 10.1186/1479-7364-7-22
Pediatric Nephrology (Berlin, Germany); Umman N, Talip Petmezci M et. al.

May 14th, 2022 - Liver damage is uncommon in Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS). Herein, we present two cases with a diagnosis of STEC-HUS that progressed to liver damage, with findings presumably related to the ...

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

May 13th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...

Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiop...
https://doi.org/10.1182/bloodadvances.2021006416
Blood Advances; Acosta-Medina AA, Moyer AM et. al.

May 10th, 2022 - Eculizumab is effective for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome. Although lifelong therapy had been suggested, discontinuation does not universally lead to relapse. Comprehensiv...

Ocular involvement in STEC-associated hemolytic uremic syndrome.
https://doi.org/10.1007/s00467-022-05587-1 10.1016/S0022-3476(64)80337-1 10.1007/BF00858679 10.1007/s00467-018-4105-1 10.1007/s004670050248 10.1007/s00467-011-1973-z 10.1111/j.1755-3768.2009.01552.x 10.1038/eye.2012.222 10.1097/00006982-199901000-00014 10.1016/j.jpeds.2014.04.008 10.5935/0004-2749.20140099 10.1007/s00467-021-05376-2
Pediatric Nephrology (Berlin, Germany); Spizzirri AP, Cobeñas CJ et. al.

May 8th, 2022 - Hemolytic uremic syndrome (HUS) is a systemic thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, and variable kidney involvement. Extrarenal thrombotic microangiopathy occurs in central nervous system (CNS), colon, and...

Atypical hemolytic uremic syndrome induced by SARS-CoV2 infection in infants with EXOSC...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072151
Pediatric Nephrology (Berlin, Germany); Van Quekelberghe C, Latta K et. al.

May 7th, 2022 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by systemic thrombotic microangiopathy mainly in the kidneys and mostly due to genetic disorders leading to uncontrolled activation of the complement system. Severe complica...

see more →

Guidelines  4 results

Clinical guides for atypical hemolytic uremic syndrome in Japan.
https://doi.org/10.1007/s10157-016-1276-6
Clinical and Experimental Nephrology; Kato H, Nangaku M et. al.

Jul 17th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...

An international consensus approach to the management of atypical hemolytic uremic synd...
https://doi.org/10.1007/s00467-015-3076-8
Pediatric Nephrology (Berlin, Germany); Loirat C, Fakhouri F et. al.

Apr 11th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....

Guidelines for the management and investigation of hemolytic uremic syndrome.
https://doi.org/10.1007/s10157-014-0995-9
Clinical and Experimental Nephrology; Igarashi T, Ito S et. al.

Aug 8th, 2014 - Guidelines for the management and investigation of hemolytic uremic syndrome.|2014|Igarashi T,Ito S,Sako M,Saitoh A,Hataya H,|standards,diagnosis,etiology,therapy,standards,

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic urem...
https://doi.org/10.1007/s00467-008-0964-1
Pediatric Nephrology (Berlin, Germany); Ariceta G, Besbas N et. al.

Sep 19th, 2008 - This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  14 results

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

May 13th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
https://clinicaltrials.gov/ct2/show/NCT03131219

Apr 12th, 2022 - The purpose of the study is to assess the efficacy of ravulizumab to control disease activity in children and adolescents with aHUS who have not previously used a complement inhibitor (complement inhibitor treatment-naïve), as well as in complemen...

Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
https://clinicaltrials.gov/ct2/show/NCT04132375

Mar 31st, 2022 - Hemolytic uremic syndrome (HUS) is a form of thrombotic microangiopathy, characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal impairment of varying severity, which may be preceded by an episode of diarrhea with or ...

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT03518203

Dec 14th, 2021 - This clinical trial is a prospective single arm multi-institution study in children and young adults undergoing allogeneic or autologous hematopoietic stem cell transplantation who will receive early therapy with eculizumab to prevent TMA-associat...

see more →

News  73 results

GI Infections Dipped Sharply During Pandemic Restrictions
https://www.medpagetoday.com/gastroenterology/generalgastroenterology/97783

Mar 21st, 2022 - Reported gastrointestinal (GI) outbreaks in England were halved during the first 6 months of the COVID-19 pandemic compared with a similar period over the 5 years' prior, a retrospective ecological study found. From February to July 2020, there wa...

MRD-Guided Therapy Could Inform Treatment-Free Surveillance in Newly Diagnosed Multiple Myeloma
https://www.onclive.com/view/mrd-guided-therapy-could-inform-treatment-free-surveillance-in-newly-diagnosed-multiple-myeloma

Dec 12th, 2021 - Minimal residual disease (MRD), assessed through next-generation sequencing (NGS) was found to inform treatment selection and duration with daratumumab (Darzalex) plus carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) f...

Phase 3 Drug Trial for ALS Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/957004

Aug 20th, 2021 - A global phase 3 trial of ravulizumab (Ultomiris) for adults with amyotrophic lateral sclerosis (ALS) is being discontinued following a data review, its manufacturer has announced. The CHAMPION-ALS placebo-controlled trial had enrolled 382 adults ...

Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments
https://www.onclive.com/view/transplant-associated-thrombotic-microangiopathy-new-insights-emerging-treatments

Jul 22nd, 2021 - Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of stem cell transplants that can occur with peripherally mobilized stem cells or bone marrow-derived stem cells. TA-TMA remains a difficult complication to address, with ...

Role of Leptin in the MASP-2 Pathway
https://www.onclive.com/view/role-of-leptin-in-the-masp-2-pathway

Apr 26th, 2021 - Samer Khaled, MD: We’ll move on to our next segment and talk about an evolving novel therapy that’s being introduced by Omeros. This is a MASP-2 [mannan-binding lectin serine protease] inhibitor that inhibits the lectin pathway. Just to start with...

see more →

Patient Education  4 results see all →